We showed previously that HL-60 and F9 mouse embryonal carcinoma cells will take up and deblock peracetylated Gal1-4GlcNAc-O-naphthalenemethanol (Gal1-4GlcNAc-NM) and use the disaccharide as a primer of oligosaccharide chains (Sarkar, A. K., Fritz, T. A., Taylor, W. H., and Esko, J. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3323-3327). We now report that another disaccharide, acetylated GlcNAc1-3Gal-naphthalenemethanol (GlcNAc1-3Gal-NM), has even greater potency and that both compounds will inhibit sialyl Lewis X (sLe x )-dependent cell adhesion. When fed to U937 cells, acetylated forms of Gal1-4GlcNAc-NM and GlcNAc1-3Gal-NM primed oligosaccharides in a dosedependent manner. Analysis of compounds assembled on Gal1-4GlcNAc-NM showed only one product, namely Gal1-4(Fuc␣1-3)GlcNAc-NM. In contrast, GlcNAc1-3Gal-NM generated Gal1-4GlcNAc1-3Gal-NM, Gal1-4(Fuc␣1-3)GlcNAc1-3Gal-NM, NeuAc␣2-3Gal-1-4GlcNAc1-3Gal-NM, and NeuAc␣2-3Gal1-4(Fuc␣1-3)GlcNAc1-3Gal-NM. Both compounds decreased the incorporation of [ 3 H]fucose into cellular glycoconjugates, without affecting the incorporation of [ 3 H]mannosamine, a precursor of sialic acid residues. Moreover, the overall extent of sialylation was not affected based on the reactivity of cells to fluorescein isothiocyanateconjugated Maackia amurensis lectin. Priming inhibited expression of sLe x on cell surface glycoconjugates, which reduced E-selectin-dependent cell adhesion to tumor necrosis factor-␣-activated human umbilical vein endothelial cells. GlcNAc1-3Gal-NM and Gal1-4Glc-NAc-NM represent starting points for making enzymespecific, site-directed inhibitors of glycosyltransferases that could act in living cells.